{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:23:41Z","timestamp":1787509421094,"version":"build-2736575974"},"reference-count":103,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004881","name":"Instituto Mexicano del Seguro Social","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004881","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.arcmed.2025.103326","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:56:53Z","timestamp":1769515013000},"page":"103326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mechanisms of Chemoresistance in Malignant Pleural Mesothelioma: The Regulatory Role of miRNAs"],"prefix":"10.1016","volume":"57","author":[{"given":"Andrea","family":"Martinez-Marroquin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gayt\u00e1n-Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayde\u00e9","family":"Rosas-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0530-492X","authenticated-orcid":false,"given":"Constantino","family":"L\u00f3pez-Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itzel","family":"Peralta-Salguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Cid-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4697-5973","authenticated-orcid":false,"given":"Violeta Castro","family":"Leyva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8305-4279","authenticated-orcid":false,"given":"Marlon De","family":"Ita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0688-9333","authenticated-orcid":false,"given":"Carolina","family":"Gonz\u00e1lez-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2025.103326_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/jdb7020007","article-title":"Mesothelium and Malignant Mesothelioma","volume":"7","author":"Hiriart","year":"2019","journal-title":"J Dev Biol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0002","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.arcmed.2025.103326_bib0003","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/oemed-2017-104298","article-title":"Estimation of the global burden of mesothelioma deaths from incomplete national mortality data","volume":"74","author":"Odgerel","year":"2017","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.arcmed.2025.103326_bib0004","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.arcmed.2025.103326_bib0005","unstructured":"U.S. Cancer statistics Working Group. U.S. Cancer statistics data Visualizations tool. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; https:\/\/www.cdc.gov\/cancer\/dataviz, released in June 2025. (Accessed January 6, 2025)."},{"key":"10.1016\/j.arcmed.2025.103326_bib0006","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.arcmed.2025.103326_bib0007","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"33","author":"Popat","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0008","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000527971","article-title":"Asbestos exposure and malignant pleural mesothelioma: a systematic review of literature","volume":"40","author":"Santos","year":"2023","journal-title":"Port J Public Health"},{"key":"10.1016\/j.arcmed.2025.103326_bib0009","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/JTO.0000000000000661","article-title":"A new prognostic score supporting treatment allocation for multimodality therapy for malignant pleural mesothelioma: a review of 12 years' Experience","volume":"10","author":"Opitz","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0010","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/ijms19010238","article-title":"Heterogeneous contributing factors in MPM Disease development and progression: biological advances and clinical implications","volume":"19","author":"Tolani","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.arcmed.2025.103326_bib0011","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/ijc.32931","article-title":"Survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: a population-based study","volume":"147","author":"Sirri","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.arcmed.2025.103326_bib0012","first-page":"770","article-title":"Update on epidemiology, pathophysiology, diagnosis and treatment of malignant pleural mesothelioma]","volume":"54","author":"Gopar-Nieto","year":"2016","journal-title":"Rev Med Inst Mex Seguro Soc"},{"key":"10.1016\/j.arcmed.2025.103326_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0275936","article-title":"Assessment of miR-103a-3p in leukocytes-No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis","volume":"17","author":"Jimenez-Ramirez","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.arcmed.2025.103326_bib0014","first-page":"A455","article-title":"Survival analysis of malignant pleural mesothelioma in Mexican workers","volume":"75","author":"Madrigal","year":"2018","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.arcmed.2025.103326_bib0015","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0016","first-page":"1","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"58","author":"Scherpereel","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arcmed.2025.103326_bib0017","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2174\/2211536605666160128151018","article-title":"Prognostic and therapeutic implications of MicroRNA in malignant pleural mesothelioma","volume":"5","author":"Truini","year":"2016","journal-title":"Microrna"},{"key":"10.1016\/j.arcmed.2025.103326_bib0018","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ccm.2021.08.006","article-title":"Malignant pleural mesothelioma: updates for Respiratory physicians","volume":"42","author":"Sidhu","year":"2021","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.arcmed.2025.103326_bib0019","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CCO.0000000000000697","article-title":"Malignant pleural mesothelioma: recent developments","volume":"33","author":"Sinn","year":"2021","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0020","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1158\/1055-9965.EPI-10-0346","article-title":"Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma","volume":"19","author":"Creaney","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.arcmed.2025.103326_bib0021","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1097\/JTO.0b013e3182272294","article-title":"Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma","volume":"6","author":"Hollevoet","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0022","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.arcmed.2025.103326_bib0023","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1155\/2013\/874212","article-title":"Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum","volume":"35","author":"Creaney","year":"2013","journal-title":"Dis Markers"},{"key":"10.1016\/j.arcmed.2025.103326_bib0024","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/bs.acr.2017.06.002","article-title":"Cancer hallmarks and MicroRNAs: the therapeutic connection","volume":"135","author":"Van Roosbroeck","year":"2017","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.arcmed.2025.103326_bib0025","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/nar\/gkab1256","article-title":"Reexamining assumptions about miRNA-guided gene silencing","volume":"50","author":"Kilikevicius","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.arcmed.2025.103326_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.913951","article-title":"OncomiRs as noncoding RNAs having functions in cancer: their role in immune suppression and clinical implications","volume":"13","author":"Otmani","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0027","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.tig.2021.10.002","article-title":"Classical and noncanonical functions of miRNAs in cancers","volume":"38","author":"Dragomir","year":"2022","journal-title":"Trends Genet"},{"key":"10.1016\/j.arcmed.2025.103326_bib0028","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.yexmp.2014.09.016","article-title":"Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets","volume":"97","author":"Ramirez-Salazar","year":"2014","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154947","article-title":"Deciphering signaling pathway interplay via miRNAs in malignant pleural mesothelioma","volume":"252","author":"Salman","year":"2023","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.arcmed.2025.103326_bib0030","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/jpm11020097","article-title":"Role of microRNAs in lung carcinogenesis induced by asbestos","volume":"11","author":"Bersimbaev","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.arcmed.2025.103326_bib0031","doi-asserted-by":"crossref","first-page":"82700","DOI":"10.18632\/oncotarget.12408","article-title":"Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers","volume":"7","author":"Bononi","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.arcmed.2025.103326_bib0032","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/gcc.20669","article-title":"CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis","volume":"48","author":"Guled","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.arcmed.2025.103326_bib0033","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/635748","article-title":"MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion","volume":"2015","author":"Ak","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.arcmed.2025.103326_bib0034","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1002\/ijc.25285","article-title":"Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma","volume":"127","author":"Gee","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.arcmed.2025.103326_bib0035","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/annonc\/mdt412","article-title":"Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma","volume":"24","author":"Reid","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0036","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1378\/chest.12-2770","article-title":"miR-1 induces growth arrest and apoptosis in malignant mesothelioma","volume":"144","author":"Xu","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.arcmed.2025.103326_bib0037","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/0008-5472.CAN-09-3993","article-title":"hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma","volume":"70","author":"Pass","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.arcmed.2025.103326_bib0038","doi-asserted-by":"crossref","first-page":"15805","DOI":"10.1073\/pnas.0707628104","article-title":"MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B","volume":"104","author":"Fabbri","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.arcmed.2025.103326_bib0039","doi-asserted-by":"crossref","first-page":"22809","DOI":"10.1074\/jbc.M110.100354","article-title":"Pro-tumorigenic effects of miR-31 loss in mesothelioma","volume":"285","author":"Ivanov","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.arcmed.2025.103326_bib0040","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/ncb1258","article-title":"Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance","volume":"7","author":"MacKeigan","year":"2005","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0041","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12032-014-0303-2","article-title":"Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component","volume":"31","author":"Matsumoto","year":"2014","journal-title":"Med Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0042","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/cdd.2009.109","article-title":"p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC","volume":"17","author":"Christoffersen","year":"2010","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.arcmed.2025.103326_bib0043","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2174\/13894501113149990191","article-title":"Functional role of miR-34 family in human cancer","volume":"14","author":"Wang","year":"2013","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.arcmed.2025.103326_bib0044","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1101\/gad.233585.113","article-title":"A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression","volume":"28","author":"Okada","year":"2014","journal-title":"Genes Dev"},{"key":"10.1016\/j.arcmed.2025.103326_bib0045","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1158\/1078-0432.CCR-10-3040","article-title":"Epigenetic silencing of microRNA-34b\/c plays an important role in the pathogenesis of malignant pleural mesothelioma","volume":"17","author":"Kubo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2025.103326_bib0046","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.3892\/or.2013.2351","article-title":"Downregulation of microRNA-34 induces cell proliferation and invasion of human mesothelial cells","volume":"29","author":"Tanaka","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.arcmed.2025.103326_bib0047","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/cgt.2011.50","article-title":"EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene","volume":"18","author":"Khodayari","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.arcmed.2025.103326_bib0048","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JTO.0b013e31820db125","article-title":"MicroRNAs dysregulation in human malignant pleural mesothelioma","volume":"6","author":"Balatti","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0049","first-page":"1","article-title":"An update on emerging therapeutic options for malignant pleural mesothelioma","volume":"13","author":"Davis","year":"2022","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1016\/j.arcmed.2025.103326_bib0050","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jtho.2017.05.024","article-title":"Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma","volume":"12","author":"Kao","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0051","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2217\/fon-2017-0307","article-title":"A review of bevacizumab in the treatment of malignant pleural mesothelioma","volume":"13","author":"Brosseau","year":"2017","journal-title":"Future Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0052","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/ajco.13455","article-title":"Bevacizumab plus cisplatin\/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: a Japanese safety study","volume":"17","author":"Nakano","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0053","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2025.103326_bib0054","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cllc.2023.04.004","article-title":"Short report of a phase II trial of Nintedanib in recurrent malignant pleural mesothelioma (MPM)","volume":"24","author":"Wozniak","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.arcmed.2025.103326_bib0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.20517\/2394-4722.2022.70","article-title":"Promising therapeutic potential of tumor suppressor microRNAs for malignant pleural mesothelioma","volume":"8","author":"Dixit","year":"2022","journal-title":"J Cancer Metastasis Treat"},{"key":"10.1016\/j.arcmed.2025.103326_bib0056","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2213-2600(20)30362-3","article-title":"Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial","volume":"9","author":"de Gooijer","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arcmed.2025.103326_bib0057","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"Pinto","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0058","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3390\/cancers10120471","article-title":"Chemoresistance and the self-maintaining tumor microenvironment","volume":"10","author":"Yeldag","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.arcmed.2025.103326_bib0059","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/17512433.2022.2074835","article-title":"Splicing deregulation, microRNA and notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma","volume":"15","author":"Anobile","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0060","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41416-020-0773-2","article-title":"miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer","volume":"122","author":"Barisciano","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.arcmed.2025.103326_bib0061","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13046-021-01901-1","article-title":"Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2\/STAT3 signaling","volume":"40","author":"Yang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2025.103326_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117238","article-title":"MiR-27b suppresses epithelial-mesenchymal transition and chemoresistance in lung cancer by targeting Snail1","volume":"254","author":"Zhang","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.arcmed.2025.103326_bib0063","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.7150\/thno.30372","article-title":"Identification of miR-29c and its target FBXO31 as a key regulatory mechanism in esophageal cancer chemoresistance: functional validation and clinical significance","volume":"9","author":"Li","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.arcmed.2025.103326_bib0064","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.3892\/or.2014.3481","article-title":"MiR-379\/411 cluster regulates IL-18 and contributes to drug resistance in malignant pleural mesothelioma","volume":"32","author":"Yamamoto","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.arcmed.2025.103326_bib0065","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.omtn.2017.07.001","article-title":"MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma","volume":"8","author":"Moody","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.arcmed.2025.103326_bib0066","first-page":"4161","article-title":"Inhibition of miR-18a-3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin","volume":"19","author":"Suzuki","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.arcmed.2025.103326_bib0067","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3389\/fonc.2020.00105","article-title":"Manipulating microRNAs for the treatment of malignant pleural mesothelioma: past, present and future","volume":"10","author":"Reid","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0068","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.3390\/cancers14205124","article-title":"Enhanced epithelial-to-mesenchymal transition and chemoresistance in advanced retinoblastoma tumors is driven by miR-181a","volume":"14","author":"Suresh Babu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.arcmed.2025.103326_bib0069","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/med.21739","article-title":"Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp)","volume":"41","author":"Zhang","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.arcmed.2025.103326_bib0070","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/15384047.2017.1415677","article-title":"Micro-RNA149 confers taxane resistance to malignant mesothelioma cells via regulation of P-glycoprotein expression","volume":"19","author":"Kenworthy","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.arcmed.2025.103326_bib0071","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ncrna.2021.12.001","article-title":"microRNAs in cancer chemoresistance: the sword and the shield","volume":"6","author":"Mondal","year":"2021","journal-title":"Noncoding RNA Res"},{"key":"10.1016\/j.arcmed.2025.103326_bib0072","first-page":"1193","article-title":"Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways","volume":"2","author":"Williams","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.arcmed.2025.103326_bib0073","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.3390\/cancers14194784","article-title":"Exploring MicroRNA and exosome involvement in malignant pleural mesothelioma drug response","volume":"14","author":"Johnson","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.arcmed.2025.103326_bib0074","article-title":"A comparison between the effects of over-expression of miRNA-16 and miRNA-34a on cell cycle progression of mesothelioma cell lines and on their cisplatin sensitivity","volume":"26","author":"Pinelli","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.arcmed.2025.103326_bib0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3892\/ijmm.2021.4950","article-title":"Overexpression of microRNA\u2011486 affects the proliferation and chemosensitivity of mesothelioma cell lines by targeting PIM1","volume":"47","author":"Pinelli","year":"2021","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.arcmed.2025.103326_bib0076","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-022-01305-4","article-title":"Emerging role of exosomes in cancer progression and tumor microenvironment remodeling","volume":"15","author":"Paskeh","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0077","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.drudis.2019.06.010","article-title":"Exosomal miRNA in chemoresistance, immune evasion, metastasis and progression of cancer","volume":"24","author":"Kulkarni","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.arcmed.2025.103326_bib0078","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12943-019-0991-5","article-title":"Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance","volume":"18","author":"Mashouri","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.arcmed.2025.103326_bib0079","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48133-0","article-title":"Exosomal miR-16-5p as a target for malignant mesothelioma","volume":"9","author":"Munson","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.arcmed.2025.103326_bib0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176680","article-title":"Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease","volume":"12","author":"Cavalleri","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.arcmed.2025.103326_bib0081","first-page":"2198","article-title":"Selection of microRNAs in extracellular vesicles for diagnosis of malignant pleural mesothelioma by in vitro analysis","volume":"44","author":"Jotatsu","year":"2020","journal-title":"Oncol Rep"},{"key":"10.1016\/j.arcmed.2025.103326_bib0082","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1002\/ctm2.257","article-title":"The roles of exosomes in cancer drug resistance and its therapeutic application","volume":"10","author":"Li","year":"2020","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.arcmed.2025.103326_bib0083","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2018.02.004","article-title":"Targeting the microenvironment in solid tumors","volume":"65","author":"Belli","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.arcmed.2025.103326_bib0084","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2019.07.003","article-title":"Exosomes and their role in tumorigenesis and anticancer drug resistance","volume":"45","author":"Milman","year":"2019","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.arcmed.2025.103326_bib0085","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.molonc.2014.07.011","article-title":"Acquired and intrinsic resistance in cancer immunotherapy","volume":"8","author":"Kelderman","year":"2014","journal-title":"Mol Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0086","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3389\/fonc.2020.00472","article-title":"The role of exosomal microRNA in cancer drug resistance","volume":"10","author":"Guo","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0087","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12967-021-03215-4","article-title":"The role of exosomal miRNAs in cancer","volume":"20","author":"Li","year":"2022","journal-title":"J Transl Med"},{"key":"10.1016\/j.arcmed.2025.103326_bib0088","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1165\/rcmb.2003-0238OC","article-title":"Proteomic analysis of exosomes isolated from human malignant pleural effusions","volume":"31","author":"Bard","year":"2004","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0089","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40164-021-00206-5","article-title":"MiRNA-mediated EMT and CSCs in cancer chemoresistance","volume":"10","author":"Dong","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0090","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/cac2.12138","article-title":"EMT-associated microRNAs and their roles in cancer stemness and drug resistance","volume":"41","author":"Pan","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.arcmed.2025.103326_bib0091","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.biocel.2018.06.007","article-title":"MicroRNA-17 inhibition overcomes chemoresistance and suppresses epithelial-mesenchymal transition through a DEDD-dependent mechanism in gastric cancer","volume":"102","author":"Wu","year":"2018","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0092","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1038\/onc.2013.476","article-title":"Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma","volume":"33","author":"Cioce","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.arcmed.2025.103326_bib0093","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3389\/fonc.2018.00650","article-title":"MicroRNAs for the diagnosis and management of malignant pleural mesothelioma: a literature review","volume":"8","author":"Lo Russo","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.arcmed.2025.103326_bib0094","doi-asserted-by":"crossref","first-page":"14910","DOI":"10.1074\/jbc.C800074200","article-title":"The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2","volume":"283","author":"Korpal","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.arcmed.2025.103326_bib0095","doi-asserted-by":"crossref","first-page":"20828","DOI":"10.1073\/pnas.1008301107","article-title":"miR-200 family and targets, ZEB1 and ZEB2, modulate uterine quiescence and contractility during pregnancy and labor","volume":"107","author":"Renthal","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.arcmed.2025.103326_bib0096","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1101\/gad.1640608","article-title":"The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2","volume":"22","author":"Park","year":"2008","journal-title":"Genes Dev"},{"key":"10.1016\/j.arcmed.2025.103326_bib0097","doi-asserted-by":"crossref","first-page":"814","DOI":"10.20517\/cdr.2022.56","article-title":"Butein-instigated miR-186-5p-dependent modulation of TWIST1 affects resistance to cisplatin and bioenergetics of malignant Pleural Mesothelioma cells","volume":"5","author":"Cioce","year":"2022","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.arcmed.2025.103326_bib0098","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.7150\/ijbs.13453","article-title":"Blockage of epithelial to mesenchymal transition and upregulation of let 7b are critically involved in ursolic acid induced apoptosis in malignant mesothelioma cell","volume":"12","author":"Sohn","year":"2016","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.arcmed.2025.103326_bib0099","doi-asserted-by":"crossref","first-page":"17300","DOI":"10.18632\/oncotarget.24644","article-title":"MiR-21 over-expression and Programmed Cell Death 4 down-regulation features malignant pleural mesothelioma","volume":"9","author":"Nicol\u00e8","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.arcmed.2025.103326_bib0100","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccr.2007.03.012","article-title":"Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics","volume":"11","author":"MacDiarmid","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.arcmed.2025.103326_bib0101","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2217\/epi-2016-0035","article-title":"Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer","volume":"8","author":"Reid","year":"2016","journal-title":"Epigenomics"},{"key":"10.1016\/j.arcmed.2025.103326_bib0102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186137","article-title":"Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models","volume":"12","author":"Alfaleh","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.arcmed.2025.103326_bib0103","doi-asserted-by":"crossref","first-page":"23480","DOI":"10.18632\/oncotarget.4346","article-title":"miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma","volume":"6","author":"Williams","year":"2015","journal-title":"Oncotarget"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440925001468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440925001468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:21:13Z","timestamp":1780665673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440925001468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0188440925001468"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2025.103326","relation":{},"ISSN":["0188-4409"],"issn-type":[{"value":"0188-4409","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of Chemoresistance in Malignant Pleural Mesothelioma: The Regulatory Role of miRNAs","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2025.103326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of Instituto Mexicano del Seguro Social (IMSS).","name":"copyright","label":"Copyright"}],"article-number":"103326"}}